1. Claim 1: a formula compound (1),or a pharmaceutically acceptable salt thereof, wherein R¹ is H, -C₁₋₅ alkyl,-O-lessor c8321e.83318325；-C₂₋₅ alkenyl,-O-Cque alkenyl,-C₂₋₅ alkynyl,-O-C₂₋₅ alkynyl,-Oh, halogen, - CN, - n8310； - r8311；-CO₂R⁸,-C (o) No. 8310； (r8311)；-SO₂NR⁶R⁷,HETor C₃₋₆ cycloalkyl having optionally 1-2 double bonds, wherein -C₁₋₅ alkyl,-O-lessor c8321e.83318325；-C₂₋₅ alkenyl,-O-Cque alkenyl,-C₂₋₅ alkynyl and -O-C₂₋₅ alkynyl are each optionally substituted with 1-7 halogens, and wherein HET⁽³⁾ and C₃₋₆ cycloalkyl having optionally 1-2 double bonds are optionally substituted with 1 - 3 groups of substituents that are each independently halogen, -C₁₋₃ alkyl,-O-lessor c8321c83183323,-C₂₋₃ alkenyl,-O-Cque alkenyl,-C₂₋₃ alkynyl or -O-C₂₋₃ alkynyl,in which -alkyl C₁₋₃,-O-lessor c8321c83183323,-C₂₋₃ alkenyl,-O-Cque alkenyl,-C₂₋₃ alkynyl and -O-C₂₋₃ alkynyl are each optionally substituted with 1-7 halogens； each of R⁶ and R⁷ is independently H or -C₁₋₅ alkyl；R⁸ is H or -C₁₋₅ alkyl optionally substituted with 1-7 halogens； HET⁽³⁾ is a 3-6 membered heterocyclic ring that has 1-3 groups of heteroatoms that are each independently N, NH, O, S, S (O) or S (O) ₂ and that optionally have 1 - 3 double bonds； x is 0 or 1； the dashed lines in formula (1) represent an optional double bond between 2 adjacent carbon atoms； D¹ is N or CR²；2.N or CR3；D3 is n or cr830808；Each one,R³ and R⁴ is independently H, -C₁₋₅ alkyl,-O-lessor c8321e.83318325；-C₂₋₅ alkenyl,-O-Cque alkenyl,-C₂₋₅ alkynyl,-O-C₂₋₅ alkynyl,-Oh, halogen, - CN, - n8310； - r8311；-CO₂R⁸,-C (o) No. 8310； r8311o-so8322； nr8310； r8311811；-Apartment c-83218c-83318325e；-O-lessor c8321e.83318325；-C₂₋₅ alkenyl,-O-Cque alkenyl,-C₂₋₅ alkynyl and -O-C₂₋₅ alkynyl are optionally substituted with 1-7 halogens； each R⁵ is independently -C₁₋₅ alkyl,-O-lessor c8321e.83318325；-C₂₋₅ alkenyl,-O-Cque alkenyl,-C₂₋₅ alkynyl,-O-C₂₋₅ alkynyl,-Oh, halogen, - CN, - n8310； - r8311；-CO₂R⁸,-C (o) No. 8310； r8311o-sonr8310r8311；-Apartment c-83
